Dahong Yu - Academia.edu (original) (raw)

Papers by Dahong Yu

Research paper thumbnail of A possible mechanism for growth factor enhancement of carbohydrate absorption beyond intestinal adaptation

Research paper thumbnail of OP032 Efficacy and safety of oral tofacitinib as maintenance therapy in patients with moderate to severe ulcerative colitis: results from a phase 3 randomised controlled trial

Journal of Crohn's and Colitis, 2017

Research paper thumbnail of PALLIATIVE CARE SECTION Original Research Article Efficacy of Subcutaneous Methylnaltrexone in the Treatment of Opioid-Induced Constipation: A Responder Post Hoc Analysis

Objective. Methylnaltrexone, a selective peripher- ally acting mu-opioid receptor antagonist, eff... more Objective. Methylnaltrexone, a selective peripher- ally acting mu-opioid receptor antagonist, effec- tively treats opioid-induced constipation (OIC) in patients with advanced illness and shows efficacy in patients with chronic nonmalignant pain. The objec- tive was to identify patients who achieved maximal treatment effect based on response to initial four methylnaltrexone doses.

Research paper thumbnail of TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial

Journal of Investigative Dermatology, 2020

Trial design: We report results from a phase IIa study of efficacy and safety of PF-06700841, an ... more Trial design: We report results from a phase IIa study of efficacy and safety of PF-06700841, an oral TYK2/Jak1 inhibitor, in patients with moderate-to-severe plaque psoriasis (NCT02969018). Methods: Patients were randomized to PF-06700841 30 mg once daily (QD), 60 mg QD, or placebo (4-week induction), followed by 10 mg QD, 30 mg QD, 100 mg once weekly, or placebo (8-week maintenance). The primary endpoint was week 12 change from baseline in PASI score. Secondary endpoints were the proportion of patients achieving 75% and 90% reduction from baseline PASI at week 12. Results: In total, 212 patients in 35 sites were treated; mean (SD) baseline PASI score was 20.8 (7.68). Decreases in PASI at week 12 were statistically significant compared with placebo in five treatment groups. The greatest change from baseline (least squares mean change e17.3 [95% confidence interval, e20.0 to e14.6]) was observed in the 30-mg QD continuous treatment group. Overall, 136 patients experienced treatment-emergent adverse events, including six serious adverse events in five patients and 13 discontinuations in treatment groups because of adverse events. No herpes zoster cases or major adverse cardiac events including thromboembolic events occurred. Conclusions: PF-06700841 was generally effective and well tolerated in patients with moderate-to-severe plaque psoriasis.

Research paper thumbnail of Tofacitinib for Induction Therapy in Patients with Active Ulcerative Colitis in Two Phase 3 Clinical Trials: Results by Local and Central Endoscopic Assessments

American Journal of Gastroenterology, 2016

Research paper thumbnail of Tofacitinib Has Induction Efficacy in Moderately to Severely Active Ulcerative Colitis, Regardless of Prior TNF Inhibitor Therapy

American Journal of Gastroenterology, 2016

Research paper thumbnail of Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

The New England journal of medicine, May 4, 2017

Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential efficacy... more Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial. We further evaluated the efficacy of tofacitinib as induction and maintenance therapy. We conducted three phase 3, randomized, double-blind, placebo-controlled trials of tofacitinib therapy in adults with ulcerative colitis. In the OCTAVE Induction 1 and 2 trials, 598 and 541 patients, respectively, who had moderately to severely active ulcerative colitis despite previous conventional therapy or therapy with a tumor necrosis factor antagonist were randomly assigned to receive induction therapy with tofacitinib (10 mg twice daily) or placebo for 8 weeks. The primary end point was remission at 8 weeks. In the OCTAVE Sustain trial, 593 patients who had a clinical response to induction therapy were randomly assigned to receive maintenance therapy with tofacitinib (either 5 mg or 10 mg twice daily) or placebo for 52 weeks. The p...

Research paper thumbnail of 767 Efficacy and Safety of Oral Tofacitinib As Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis: Results From Two Phase 3 Randomized Controlled Trials

Research paper thumbnail of Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial

Gastroenterology, Jan 12, 2015

Accurate biomarkers of disease activity and therapeutic response can be valuable for clinical tri... more Accurate biomarkers of disease activity and therapeutic response can be valuable for clinical trials. We performed a post-hoc analysis of data from a Phase 2 trial to assess the relationship between concentration of fecal calprotectin (FCP) and clinical and endoscopic outcomes of patients with moderate to severe ulcerative colitis receiving tofacitinib. In a double-blind, placebo-controlled, phase 2 trial, 194 patients were randomly assigned to groups given tofacitinib (0.5, 3, 10, or 15 mg twice daily) or placebo. Clinical and endoscopic outcomes were assessed at week 8 using the Mayo scoring system. Receiver operating characteristics (ROC) were used to evaluate the relationships between FCP concentration and clinical and endoscopic outcomes, and to determine the FCP cutoff concentration that correlated with patient outcome. Week 8 median concentrations of FCP were significantly lower in responders than non-responders (P<.001): clinical response, 156 mg/kg vs 725 mg/kg; clinical...

Research paper thumbnail of Growth regulation by parathyroid hormone-related peptide and vasoactive intestinal peptide in a human colon cell line (LoVo)

Bone and Mineral, 1992

We have previously idcntilicd cJcilonin gene-rciaicd pcplidc (CGRP) and substance P (SP) co-local... more We have previously idcntilicd cJcilonin gene-rciaicd pcplidc (CGRP) and substance P (SP) co-localized within ancrial vascuiaium. and dispcrscd throughout ihc stroma of bovine paralhyroid glands-(m Tissue Rcs 261:339. 1990). Although many of Ihe nerves within tic

Research paper thumbnail of Growth Factor Enhancement of Intestinal Adaptation and Function Following Massive Small Bowel Resection. • 719

Research paper thumbnail of 1124-192 Rosiglitazone reduces novel biomarkers of cardiovascular disease in subjects with type 2 diabetes mellitus already on statin therapy

Journal of the American College of Cardiology, 2004

a set of independent risk factors. The key findings, relative risks and 95% confidence intervals ... more a set of independent risk factors. The key findings, relative risks and 95% confidence intervals were calculated and are presented below. Results: Conclusion. The data demonstrate that in renal transplant patients traditional risk factors such as age, diabetes, previous coronary heart disease and lipid values are major determinants of cardiac risk. The analysis also demonstrates that renal function and rejection episodes are independent risk factors for cardiac events.

Research paper thumbnail of Hepatocyte growth factor up-regulates SGLT1 and GLUT5 gene expression after massive small bowel resection

Journal of Pediatric Surgery, 1998

Research paper thumbnail of Hepatocyte growth factor enhances intestinal mucosal cell function and mass in vivo

Journal of Pediatric Surgery, 1997

Research paper thumbnail of Transfection of the sodium/glucose cotransporter into colon mucosa: A novel treatment for short bowel syndrome

Journal of Pediatric Surgery, 2002

Short bowel syndrome results from small intestine loss but frequently is associated with survival... more Short bowel syndrome results from small intestine loss but frequently is associated with survival of the colon. This study was designed to determine if colonic mucosa could be induced to absorb galactose by tranfection of the sodium glucose cotransporter, SGLT-1 into a colonic segment. Using 10 rats, a 7-cm segment of colon was infused for 1 hour with a solution containing 50 microg/mL of a plasmid with or without an SGLT-1 insert. An 80% small bowel resection was performed, and the segment was interposed into the small bowel. On the third day [14C] galactose absorption was measured. Mucosal RNA was extracted, and relative band intensities were measured using primers for SGLT-1. Statistical analysis was performed using the Student&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39;s t test and expressed as mean +/- SEM. Rats transfected with the SGLT-1 plasmid showed a significant increase (194%) in galactose absorption compared with controls. Transfected animals also showed high levels of of SGLT-1 transcription when compared with controls (792% increase). These data show that in vivo exposure of colon mucosa to a plasmid containing SGLT-1 allows transfer of that gene into enterocytes. Expression of SGLT-1 can create an absorptive segment that may in part alleviate the malabsorption associated with short bowel syndrome.

Research paper thumbnail of Glucagonlike peptide-2 enhances small intestinal absorptive function and mucosal mass in vivo

Journal of Pediatric Surgery, 1999

Purpose: Glucagonlike peptide-(GLP-2) is a 33-amino acid peptide that appears to be highly tissue... more Purpose: Glucagonlike peptide-(GLP-2) is a 33-amino acid peptide that appears to be highly tissue specific for the intestine. This study was designed to examine the effect of systemically administered GLP-2 on intestinal absorptive function and mucosal mass, and determine the in vivo dose-response curves for this new peptide.

Research paper thumbnail of Enteral glutamine does not enhance the effects of hepatocyte growth factor in short bowel syndrome

Journal of Pediatric Surgery, 1998

Research paper thumbnail of Enhancement of intestinal adaptation by hepatocyte growth factor

Journal of Pediatric Surgery, 1998

Research paper thumbnail of P245 Evaluation of the relationship between fecal calprotectin concentrations and clinical and endoscopic outcome measures in a phase 2 study of tofacitinib, an oral janus kinase inhibitor, in active ulcerative colitis

Journal of Crohn's and Colitis, 2013

Research paper thumbnail of The differential effect of hepatocyte growth factor on intestinal adaptation depends on the timing of exposure

Research paper thumbnail of A possible mechanism for growth factor enhancement of carbohydrate absorption beyond intestinal adaptation

Research paper thumbnail of OP032 Efficacy and safety of oral tofacitinib as maintenance therapy in patients with moderate to severe ulcerative colitis: results from a phase 3 randomised controlled trial

Journal of Crohn's and Colitis, 2017

Research paper thumbnail of PALLIATIVE CARE SECTION Original Research Article Efficacy of Subcutaneous Methylnaltrexone in the Treatment of Opioid-Induced Constipation: A Responder Post Hoc Analysis

Objective. Methylnaltrexone, a selective peripher- ally acting mu-opioid receptor antagonist, eff... more Objective. Methylnaltrexone, a selective peripher- ally acting mu-opioid receptor antagonist, effec- tively treats opioid-induced constipation (OIC) in patients with advanced illness and shows efficacy in patients with chronic nonmalignant pain. The objec- tive was to identify patients who achieved maximal treatment effect based on response to initial four methylnaltrexone doses.

Research paper thumbnail of TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial

Journal of Investigative Dermatology, 2020

Trial design: We report results from a phase IIa study of efficacy and safety of PF-06700841, an ... more Trial design: We report results from a phase IIa study of efficacy and safety of PF-06700841, an oral TYK2/Jak1 inhibitor, in patients with moderate-to-severe plaque psoriasis (NCT02969018). Methods: Patients were randomized to PF-06700841 30 mg once daily (QD), 60 mg QD, or placebo (4-week induction), followed by 10 mg QD, 30 mg QD, 100 mg once weekly, or placebo (8-week maintenance). The primary endpoint was week 12 change from baseline in PASI score. Secondary endpoints were the proportion of patients achieving 75% and 90% reduction from baseline PASI at week 12. Results: In total, 212 patients in 35 sites were treated; mean (SD) baseline PASI score was 20.8 (7.68). Decreases in PASI at week 12 were statistically significant compared with placebo in five treatment groups. The greatest change from baseline (least squares mean change e17.3 [95% confidence interval, e20.0 to e14.6]) was observed in the 30-mg QD continuous treatment group. Overall, 136 patients experienced treatment-emergent adverse events, including six serious adverse events in five patients and 13 discontinuations in treatment groups because of adverse events. No herpes zoster cases or major adverse cardiac events including thromboembolic events occurred. Conclusions: PF-06700841 was generally effective and well tolerated in patients with moderate-to-severe plaque psoriasis.

Research paper thumbnail of Tofacitinib for Induction Therapy in Patients with Active Ulcerative Colitis in Two Phase 3 Clinical Trials: Results by Local and Central Endoscopic Assessments

American Journal of Gastroenterology, 2016

Research paper thumbnail of Tofacitinib Has Induction Efficacy in Moderately to Severely Active Ulcerative Colitis, Regardless of Prior TNF Inhibitor Therapy

American Journal of Gastroenterology, 2016

Research paper thumbnail of Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

The New England journal of medicine, May 4, 2017

Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential efficacy... more Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial. We further evaluated the efficacy of tofacitinib as induction and maintenance therapy. We conducted three phase 3, randomized, double-blind, placebo-controlled trials of tofacitinib therapy in adults with ulcerative colitis. In the OCTAVE Induction 1 and 2 trials, 598 and 541 patients, respectively, who had moderately to severely active ulcerative colitis despite previous conventional therapy or therapy with a tumor necrosis factor antagonist were randomly assigned to receive induction therapy with tofacitinib (10 mg twice daily) or placebo for 8 weeks. The primary end point was remission at 8 weeks. In the OCTAVE Sustain trial, 593 patients who had a clinical response to induction therapy were randomly assigned to receive maintenance therapy with tofacitinib (either 5 mg or 10 mg twice daily) or placebo for 52 weeks. The p...

Research paper thumbnail of 767 Efficacy and Safety of Oral Tofacitinib As Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis: Results From Two Phase 3 Randomized Controlled Trials

Research paper thumbnail of Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial

Gastroenterology, Jan 12, 2015

Accurate biomarkers of disease activity and therapeutic response can be valuable for clinical tri... more Accurate biomarkers of disease activity and therapeutic response can be valuable for clinical trials. We performed a post-hoc analysis of data from a Phase 2 trial to assess the relationship between concentration of fecal calprotectin (FCP) and clinical and endoscopic outcomes of patients with moderate to severe ulcerative colitis receiving tofacitinib. In a double-blind, placebo-controlled, phase 2 trial, 194 patients were randomly assigned to groups given tofacitinib (0.5, 3, 10, or 15 mg twice daily) or placebo. Clinical and endoscopic outcomes were assessed at week 8 using the Mayo scoring system. Receiver operating characteristics (ROC) were used to evaluate the relationships between FCP concentration and clinical and endoscopic outcomes, and to determine the FCP cutoff concentration that correlated with patient outcome. Week 8 median concentrations of FCP were significantly lower in responders than non-responders (P<.001): clinical response, 156 mg/kg vs 725 mg/kg; clinical...

Research paper thumbnail of Growth regulation by parathyroid hormone-related peptide and vasoactive intestinal peptide in a human colon cell line (LoVo)

Bone and Mineral, 1992

We have previously idcntilicd cJcilonin gene-rciaicd pcplidc (CGRP) and substance P (SP) co-local... more We have previously idcntilicd cJcilonin gene-rciaicd pcplidc (CGRP) and substance P (SP) co-localized within ancrial vascuiaium. and dispcrscd throughout ihc stroma of bovine paralhyroid glands-(m Tissue Rcs 261:339. 1990). Although many of Ihe nerves within tic

Research paper thumbnail of Growth Factor Enhancement of Intestinal Adaptation and Function Following Massive Small Bowel Resection. • 719

Research paper thumbnail of 1124-192 Rosiglitazone reduces novel biomarkers of cardiovascular disease in subjects with type 2 diabetes mellitus already on statin therapy

Journal of the American College of Cardiology, 2004

a set of independent risk factors. The key findings, relative risks and 95% confidence intervals ... more a set of independent risk factors. The key findings, relative risks and 95% confidence intervals were calculated and are presented below. Results: Conclusion. The data demonstrate that in renal transplant patients traditional risk factors such as age, diabetes, previous coronary heart disease and lipid values are major determinants of cardiac risk. The analysis also demonstrates that renal function and rejection episodes are independent risk factors for cardiac events.

Research paper thumbnail of Hepatocyte growth factor up-regulates SGLT1 and GLUT5 gene expression after massive small bowel resection

Journal of Pediatric Surgery, 1998

Research paper thumbnail of Hepatocyte growth factor enhances intestinal mucosal cell function and mass in vivo

Journal of Pediatric Surgery, 1997

Research paper thumbnail of Transfection of the sodium/glucose cotransporter into colon mucosa: A novel treatment for short bowel syndrome

Journal of Pediatric Surgery, 2002

Short bowel syndrome results from small intestine loss but frequently is associated with survival... more Short bowel syndrome results from small intestine loss but frequently is associated with survival of the colon. This study was designed to determine if colonic mucosa could be induced to absorb galactose by tranfection of the sodium glucose cotransporter, SGLT-1 into a colonic segment. Using 10 rats, a 7-cm segment of colon was infused for 1 hour with a solution containing 50 microg/mL of a plasmid with or without an SGLT-1 insert. An 80% small bowel resection was performed, and the segment was interposed into the small bowel. On the third day [14C] galactose absorption was measured. Mucosal RNA was extracted, and relative band intensities were measured using primers for SGLT-1. Statistical analysis was performed using the Student&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39;s t test and expressed as mean +/- SEM. Rats transfected with the SGLT-1 plasmid showed a significant increase (194%) in galactose absorption compared with controls. Transfected animals also showed high levels of of SGLT-1 transcription when compared with controls (792% increase). These data show that in vivo exposure of colon mucosa to a plasmid containing SGLT-1 allows transfer of that gene into enterocytes. Expression of SGLT-1 can create an absorptive segment that may in part alleviate the malabsorption associated with short bowel syndrome.

Research paper thumbnail of Glucagonlike peptide-2 enhances small intestinal absorptive function and mucosal mass in vivo

Journal of Pediatric Surgery, 1999

Purpose: Glucagonlike peptide-(GLP-2) is a 33-amino acid peptide that appears to be highly tissue... more Purpose: Glucagonlike peptide-(GLP-2) is a 33-amino acid peptide that appears to be highly tissue specific for the intestine. This study was designed to examine the effect of systemically administered GLP-2 on intestinal absorptive function and mucosal mass, and determine the in vivo dose-response curves for this new peptide.

Research paper thumbnail of Enteral glutamine does not enhance the effects of hepatocyte growth factor in short bowel syndrome

Journal of Pediatric Surgery, 1998

Research paper thumbnail of Enhancement of intestinal adaptation by hepatocyte growth factor

Journal of Pediatric Surgery, 1998

Research paper thumbnail of P245 Evaluation of the relationship between fecal calprotectin concentrations and clinical and endoscopic outcome measures in a phase 2 study of tofacitinib, an oral janus kinase inhibitor, in active ulcerative colitis

Journal of Crohn's and Colitis, 2013

Research paper thumbnail of The differential effect of hepatocyte growth factor on intestinal adaptation depends on the timing of exposure